BeiGene Breaks Ground on a New Manufacturing and Clinical R&D Center

Subscribe. Be the voice of the Free Press

Flagship U.S. Facility Will Include Biologic Manufacturing and Late Stage

Research and Clinical Development of Innovative Cancer Medicines

Sixth U.S. Location Adds to Global Expansion and Brings New Jobs to New Jersey


By Adam Rizvi, TIO. Hopewell, N.J., CAMBRIDGE, Mass., BASEL, Switzerland, and BEIJING – April 29, 2022 — BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company aimed at developing efficient and affordable medicines for patients internationally, today announced the opening of its flagship U.S. manufacturing and clinical R&D center at the Princeton West Innovation Campus in Hopewell, New Jersey.


“Our planned flagship U.S. R&D and manufacturing center supports our commitment to fight for life for people living with cancer around the world, through state-of-the-art commercial-stage biologic pharmaceutical manufacturing, late-stage research, and clinical development capabilities,” said John Oyler, Co-Founder, Chairman, and CEO of BeiGene. “The Princeton-Hopewell area is an excellent location for BeiGene and the thriving life science community, with a deep talent pool as we continue to advance our pipeline of innovative cancer medicines and work to diversify our global supply chain.”


Approximately 400,000 square feet of dedicated commercial-stage biologic pharmaceutical production space, with a capacity of up to 16,000 liters of biologics formula, is expected to be built in the first phase. The first phase of construction is planned to last until 2024. To support its sustained growth and dedication to providing life-saving oncology drugs, BeiGene plans to hire hundreds of additional employees from the area’s outstanding labor pool.

Also, Read: What Is At The Heart of Ukraine Story?


“BeiGene’s plans for hundreds of new jobs in New Jersey speak to our efforts to grow our state’s business-friendly environment and to our commitment to fostering innovation,” said Governor Phil Murphy. “We are proud to welcome BeiGene to the Princeton area and look forward to the company manufacturing innovative cancer medicines in its new state-of-the-art facility.”


BeiGene purchased the Hopewell site from Lincoln Equities Group in November 2021 and has hired DPR Construction as the construction manager and IPS as the architect and engineer. The property contains almost one million square feet of developable land available for future development.


Added Oyler: “At BeiGene, we are committed to not only delivering innovative and affordable medicines but also to upholding the highest standards of ethics and integrity, operational excellence, and environmental stewardship. This commitment applies to everything we do, including the development of BeiGene’s Hopewell project.”


Also, Read: I Wish Welcomes First Lady of New Jersey to Ireland/US STEM Twinning School


“As a leader with a long history in New Jersey’s biotech industry, Hopewell Township welcomes BeiGene to our community,” said Hopewell Mayor Courtney Peters-Manning  “We are pleased that BeiGene will bring their state-of-the-art technologies, manufacturing, and R&D center to Hopewell, whose products will help countless people all over the world. We look forward to continuing to work with BeiGene and are excited about what will be produced here in Hopewell.”


In the U. S., BeiGene has offices in San Mateo and Emeryville, California, Cambridge, Massachusetts, Ridgefield Park, New Jersey, and Fulton, Maryland. The organization has more than 30 offices worldwide, spread across five continents.


Also, Read: America played a decisive role in removing Imran Khan as the Prime Minister of Pakistan


Curated By Leen Hamade

Leave a Reply

Your email address will not be published. Required fields are marked *